Fresenius SE & Co. KGaA Total Liabilities
Fresenius SE & Co. KGaA total liabilities. Based on the latest financial reports, Fresenius SE & Co. KGaA (FRE) has total liabilities worth €23.19 Billion EUR (≈ $27.11 Billion USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See FRE defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Total Liabilities of Fresenius SE & Co. KGaA (2002–2024)
Total liabilities of Fresenius SE & Co. KGaA from 2002 to 2024. This chart illustrates how Fresenius SE & Co. KGaA's total liabilities have evolved over time, based on quarterly financial data. Check FRE asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Fresenius SE & Co. KGaA Competitors by Total Liabilities
The table below lists competitors of Fresenius SE & Co. KGaA ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Celltrion Inc
KO:068270
|
Korea | ₩5.65 Trillion |
|
FANUC CORP.UNSP.ADR 1/10
F:FUCA
|
Germany | €195.14 Billion |
|
Fiserv Inc.
NASDAQ:FISV
|
USA | $49.49 Billion |
|
Givaudan SA
SW:GIVN
|
Switzerland | CHF7.68 Billion |
|
KONE Oyj
HE:KNEBV
|
Finland | €6.23 Billion |
|
HOCHTIEF Aktiengesellschaft
F:HOT
|
Germany | €26.83 Billion |
|
IMPERIAL BRANDS PLC ADR/1
F:ITBA
|
Germany | €23.28 Billion |
|
Okta Inc
NASDAQ:OKTA
|
USA | $2.17 Billion |
Liability Composition Analysis (2002–2024)
This chart breaks down Fresenius SE & Co. KGaA's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Fresenius SE & Co. KGaA balance sheet assets.
Liquidity & Leverage Metrics
Fresenius SE & Co. KGaA Total Liabilities Ratios Explained
Fresenius SE & Co. KGaA total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.26 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 0.25 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.25 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.55 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Fresenius SE & Co. KGaA's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Fresenius SE & Co. KGaA (2002–2024)
The table below shows the annual total liabilities of Fresenius SE & Co. KGaA from 2002 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €23.26 Billion ≈ $27.19 Billion |
-9.26% |
| 2023-12-31 | €25.63 Billion ≈ $29.97 Billion |
-42.00% |
| 2022-12-31 | €44.20 Billion ≈ $51.67 Billion |
+3.57% |
| 2021-12-31 | €42.67 Billion ≈ $49.89 Billion |
+5.05% |
| 2020-12-31 | €40.62 Billion ≈ $47.49 Billion |
+0.49% |
| 2019-12-31 | €40.43 Billion ≈ $47.26 Billion |
+27.55% |
| 2018-12-31 | €31.70 Billion ≈ $37.05 Billion |
+0.90% |
| 2017-12-31 | €31.41 Billion ≈ $36.73 Billion |
+26.45% |
| 2016-12-31 | €24.84 Billion ≈ $29.04 Billion |
+2.57% |
| 2015-12-31 | €24.22 Billion ≈ $28.32 Billion |
+2.05% |
| 2014-12-31 | €23.73 Billion ≈ $27.75 Billion |
+24.74% |
| 2013-12-31 | €19.03 Billion ≈ $22.24 Billion |
+8.67% |
| 2012-12-31 | €17.51 Billion ≈ $20.47 Billion |
+11.20% |
| 2011-12-31 | €15.74 Billion ≈ $18.41 Billion |
+6.86% |
| 2010-12-31 | €14.73 Billion ≈ $17.22 Billion |
+11.36% |
| 2009-12-31 | €13.23 Billion ≈ $15.47 Billion |
-2.73% |
| 2008-12-31 | €13.60 Billion ≈ $15.90 Billion |
+13.47% |
| 2007-12-31 | €11.99 Billion ≈ $14.01 Billion |
+0.54% |
| 2006-12-31 | €11.92 Billion ≈ $13.94 Billion |
+35.20% |
| 2005-12-31 | €8.82 Billion ≈ $10.31 Billion |
+33.91% |
| 2004-12-31 | €6.59 Billion ≈ $7.70 Billion |
+28.29% |
| 2003-12-31 | €5.13 Billion ≈ $6.00 Billion |
-7.45% |
| 2002-12-31 | €5.55 Billion ≈ $6.48 Billion |
-- |
About Fresenius SE & Co. KGaA
Fresenius SE & Co. KGaA, a health care company, provides products and services for chronically ill patients. It operates through Fresenius Kabi and Fresenius Helios segment. The Fresenius Kabi segment engages in the therapy and care of critically and chronically ill patients; enteral and parenteral nutrition products; medical technologies, as well as disposables, infusions pumps, apheresis machin… Read more